<ul><li>Unity Biotechnology has laid off its entire workforce, including top executives, in an effort to conserve cash and assess potential exit strategies.</li><li>All remaining employees, including CEO Anirvan Ghosh, will exit by May 15, with plans to spend $3.7 million on severance.</li><li>Unity, known for anti-aging treatments, gained attention for targeting senescent cells but struggled with unsuccessful trials, resulting in losses exceeding $510 million.</li><li>With no drugs reaching the market and hopes pinned on a diabetic eye disease treatment, Unity faces challenges in a biotech landscape where innovation success is uncertain.</li></ul>

Unity Biotechnology has eliminated the entire workforce as strategic options dwindle

Discover more